• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

The Top 5 DE&I Stories in 2023

Feature
Article

As companies continued to expand their DE&I efforts, Pharm Exec was there to cover it in 2023.

Equity for Women in Healthcare: 131 Years is Too Long to Wait

Closing the gender gap in pharma—and how we get there together.

Q&A with Amy West, Head of US Digital Health & Innovation Strategy at Novo Nordisk

Amy West, Head of US Digital Health & Innovation Strategy at Novo Nordisk, shares her insights on fostering collaboration, embracing change, and her compelling vision to revolutionize digital transformation and innovation in the field of healthcare.

Pharma's ESG Equation: Materiality and Strategy are Key

Life sciences executives who are confronted by too many choices in launching their environmental, social, and governance programs can leverage these two foundational tools to hone in on the set of issues, actions, and disclosures they should prioritize to create value.

DE&I in Pharma: A Shared Aim Promoting Inclusivity from Non-Leadership Roles

In today's changing workplace environment—one forever altered by the pandemic and the new approaches it spawned—employees at all levels play a vital role in developing and advancing inclusive behaviors across an organization and beyond.

Tough—But Rewarding: The Evolution of the Chief Diversity Officer

What Smita Pillai, global chief diversity, equity, and inclusion (DE&I) officer, Regeneron, learned from two decades in DE&I roles.

Related Videos
Related Content